<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
LIVE WEBINAR

Targeting KRAS mutations: Latest therapeutic approaches and clinical insights


   27 August 2026 - 4pm GMT | 11am EST | 8am PT

KRAS-targeted therapy is advancing quickly, with new clinical results accelerating interest in G12C, G12D, G12V, pan-KRAS, and pan-RAS(ON) approaches. In this webinar, Michael Boice and Amy Wesa will explore the latest KRAS landscape, key clinical insights, and emerging combination strategies shaping drug development in NSCLC, colorectal, and pancreatic cancer.

The session is designed for pharma and biotech teams building the next generation of KRAS-directed programmes.

Join this webinar to:

  • Evaluate the latest clinical data to identify emerging trends in efficacy, durability, patient selection, and biomarker-driven development strategies.
  • Assess the opportunities and challenges shaping next-generation KRAS programmes and their implications for drug development decision-making.
  • Explore the combination strategies showing the greatest promise for improving outcomes beyond KRAS monotherapy.
  • Learn how translational models, preclinical platforms, and integrated data approaches can help de-risk KRAS programmes and accelerate pipeline advancement.

Meet Our Speakers

amy-wesa-26Amy Wesa, PhD

Head of Platform Enablement, Champions Oncology


Dr. Wesa brings more than 20 years of experience leading translational research across immuno-oncology and cell and gene therapy. Throughout her career, she has shaped translational R&D strategy for multiple programs from early development through Phase III clinical trials, helping teams connect scientific insight with smarter clinical decision-making.

She has held senior leadership roles across biotech and oncology research, including VP of Precision Medicine and Biomarkers at IO Biotech, SVP of Preclinical and Translational Research at Vita Therapeutics, and VP of Research and Development at Champions Oncology. A former faculty member at the University of Pittsburgh School of Medicine, Dr. Wesa holds a PhD in Cancer Biology from Wayne State University and brings deep scientific rigor, translational expertise, and real-world development experience to today’s KRAS landscape.

michael-boiceMichael Boice, PhD

Senior Director, Champions Oncology



Michael Boice, PhD, is a preclinical oncology expert with 10+ years of experience in cancer biology and drug discovery, with a focus on hematological malignancies. He earned his doctorate from Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, where his research explored the molecular drivers of lymphoma and tumor suppression.

Michael has held senior roles across leading CRO's, spanning scientific engagement, business development, and new product strategy. He has also co-founded a biotechnology company, leading fundraising, licensing, and product development efforts.

Now a Senior Director at Champions Oncology, Michael brings a unique combination of scientific depth and commercial perspective, helping biotech and pharma partners design smarter studies and translate data into better development decisions.